5198 related articles for article (PubMed ID: 393386)
1. cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma.
Karakousis CP; Getaz EP; Bjornsson S; Henderson ES; Irequi M; Martinez L; Ospina J; Cavins J; Preisler H; Holyoke E; Holtermann O
Cancer Treat Rep; 1979; 63(11-12):2009-10. PubMed ID: 393386
[TBL] [Abstract][Full Text] [Related]
2. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.
Goodnight JE; Moseley HS; Eilber FR; Sarna G; Morton DL
Cancer Treat Rep; 1979; 63(11-12):2005-7. PubMed ID: 393385
[TBL] [Abstract][Full Text] [Related]
3. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.
Hill GJ; Metter GE; Krementz ET; Fletcher WS; Golomb FM; Ramirez G; Grage TB; Moss SE
Cancer Treat Rep; 1979; 63(11-12):1989-92. PubMed ID: 393384
[No Abstract] [Full Text] [Related]
4. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
6. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
[TBL] [Abstract][Full Text] [Related]
7. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Young RC; Von Hoff DD; Gormley P; Makuch R; Cassidy J; Howser D; Bull JM
Cancer Treat Rep; 1979; 63(9-10):1539-44. PubMed ID: 387224
[TBL] [Abstract][Full Text] [Related]
8. Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Treat Rep; 1984 Oct; 68(10):1211-4. PubMed ID: 6525593
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis.
Chary KK; Higby DJ; Henderson ES; Swinerton KD
Cancer Treat Rep; 1977; 61(3):367-70. PubMed ID: 266972
[TBL] [Abstract][Full Text] [Related]
10. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.
Pritchard KI; Quirt IC; Cowan DH; Osoba D; Kutas GJ
Cancer Treat Rep; 1980; 64(10-11):1123-6. PubMed ID: 7459898
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
12. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
McClay EF; Mastrangelo MJ; Bellet RE; Berd D
Cancer Treat Rep; 1987 May; 71(5):465-9. PubMed ID: 3567970
[TBL] [Abstract][Full Text] [Related]
15. Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin.
Kostinas JE; Leone LA; Cuttner J; Vinciguerra V; Green M; De Bellis R; Pajak TF
Cancer Treat Rep; 1979 Feb; 63(2):197-200. PubMed ID: 376132
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
Chauvergne J; Bui NB; Cappelaere P; Gary-Bobo J; Guerrin J; Armand JP; Durand M
Sem Hop; 1982 Dec; 58(46):2697-701. PubMed ID: 6297068
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
[No Abstract] [Full Text] [Related]
18. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
19. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]